Prescription CBD's liver signal was mostly about the drug alongside it
At 10 to 25mg/kg a day for severe epilepsy, liver enzymes above three times normal appeared in 30% on both valproate and clobazam, 21% on valproate alone, 4% on clobazam alone, 3% on neither.
What the study found
The liver signal tracks valproate more than cannabidiol
Raised liver enzymes are the flagged risk of prescription cannabidiol, and the rate turns on which other seizure medicines the patient takes. Above three times normal: 30% on both valproate and clobazam, 21% on valproate alone, 4% on clobazam alone, 3% on neither.
The caveat · Far above what consumers take
These rates come from patients with severe epilepsy on cannabidiol at 10 to 25mg/kg/day, far above what consumers take. NIH's LiverTox reference gives 21% for the valproate-and-clobazam group where the label gives 30%, attributing its figure to extension studies rather than to these trials.